SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Michela Triolo, Cristina Della Corte, Massimo Colombo, Impact of HBV therapy on the incidence of hepatocellular carcinoma, Liver International, 2014, 34,
  2. You have free access to this content2
    JSH Guidelines for the Management of Hepatitis B Virus Infection, Hepatology Research, 2014, 44,
  3. 3
    Chien-Hung Chen, Sheng-Nan Lu, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion, Hepatology International, 2014,

    CrossRef

  4. 4
    Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan, Vaccine therapies for chronic hepatitis B: can we go further?, Frontiers of Medicine, 2014, 8, 1, 17

    CrossRef

  5. You have free access to this content5
    C. Popalis, L. T. F. Yeung, S. C. Ling, V. Ng, E. A. Roberts, Chronic hepatitis B virus (HBV) infection in children: 25 years' experience, Journal of Viral Hepatitis, 2013, 20, 4
  6. 6
    Jeong Won Jang, Management of viral hepatitis in patients with hepatocellular carcinoma, Journal of the Korean Medical Association, 2013, 56, 11, 1001

    CrossRef

  7. 7
    Ching-Lung Lai, Man-Fung Yuen, Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy, Hepatology, 2013, 57, 1
  8. 8
    Yun-Fan Liaw, Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B, Hepatology, 2013, 58, 5
  9. 9
    Ching-Lung Lai, Man-Fung Yuen, Reply:, Hepatology, 2013, 58, 5
  10. 10
    Dao-Zhen Xu, Xuan-Yi Wang, Xin-Liang Shen, Guo-Zhong Gong, Hong Ren, Li-Min Guo, Ai-Min Sun, Min Xu, Lan-Juan Li, Xin-Hui Guo, Zhen Zhen, Hui-Fen Wang, Huan-Yu Gong, Cheng Xu, Nan Jiang, Chen Pan, Zuo-Jiong Gong, Ji-Ming Zhang, Jia Shang, Jie Xu, Qing Xie, Tie-Feng Wu, Wen-Xiang Huang, Yong-Guo Li, Jing Xu, Zheng-Hong Yuan, Bin Wang, Kai Zhao, Yu-Mei Wen, Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings, Journal of Hepatology, 2013, 59, 3, 450

    CrossRef

  11. You have free access to this content11
    Soji Shimomura, Shuhei Nishiguchi, Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection, Hepatology Research, 2012, 42, 1
  12. 12
    Giuseppe Cabibbo, Marcello Maida, Chiara Genco, Michela Antonucci, Calogero Cammà, Causes of and Prevention Strategies for Hepatocellular Carcinoma, Seminars in Oncology, 2012, 39, 4, 374

    CrossRef

  13. 13
    Danbi Lee, Young-Hwa Chung, Sae Hwan Lee, Sung Eun Kim, Yoon-Seon Lee, Kang Mo Kim, Young Suk Lim, Han Chu Lee, Yung Sang Lee, Eunsil Yu, Effect of Response to Interferon-a Therapy on the Occurrence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B, Digestive Diseases, 2012, 30, 6, 568

    CrossRef

  14. 14
    Cristina Della Corte, Massimo Colombo, Surveillance for Hepatocellular Carcinoma, Seminars in Oncology, 2012, 39, 4, 384

    CrossRef

  15. 15
    Stephen D. Walter, Xin Sun, Diane Heels-Ansdell, Gordon Guyatt, Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers, Journal of Clinical Epidemiology, 2012, 65, 9, 940

    CrossRef

  16. 16
    Anahat Dhillon, Randolph H. Steadman, Anesthesia and Uncommon Diseases, 2012,

    CrossRef

  17. 17
    Yuk-Fai Lam, Man-Fung Yuen, Wai-Kay Seto, Ching-Lung Lai, Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety, Current Hepatitis Reports, 2011, 10, 4, 235

    CrossRef

  18. 18
    Anna Suk-Fong Lok, Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?, Journal of Gastroenterology and Hepatology, 2011, 26, 2
  19. 19
    Hakan Senturk, Birol Baysal, Veysel Tahan, Hasan Zerdali, Resat Ozaras, Fehmi Tabak, Ali Mert, Billur Canbakan, Omur Tabak, Gulsen Ozbay, Long-Term Effect of Interferon Therapy in Patients with HBeAg Positive Chronic Hepatitis B Infection, Digestive Diseases and Sciences, 2011, 56, 1, 208

    CrossRef

  20. 20
    Hui Jin, Ning Pan, Yi Mou, Bei Wang, Pei Liu, Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression, Hepatology Research, 2011, 41, 6
  21. 21
    Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn, Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection, Oncology, 2011, 81, s1, 41

    CrossRef

  22. 22
    Myron J. Tong, Calvin Q. Pan, Hie-Won Hann, Kris V. Kowdley, Steven-Huy B. Han, Albert D. Min, Truong-Sinh Leduc, The Management of Chronic Hepatitis B in Asian Americans, Digestive Diseases and Sciences, 2011, 56, 11, 3143

    CrossRef

  23. 23
    Man-Fung Yuen, Ching-Lung Lai, Treatment of chronic hepatitis B: Evolution over two decades, Journal of Gastroenterology and Hepatology, 2011, 26,
  24. 24
    Helen S. Te, Antiviral Therapy: Analysis of Long-term Efficacy and Safety, Current Hepatitis Reports, 2010, 9, 4, 214

    CrossRef

  25. 25
    Masao Omata, Laurentius A. Lesmana, Ryosuke Tateishi, Pei-Jer Chen, Shi-Ming Lin, Haruhiko Yoshida, Masatoshi Kudo, Jeong Min Lee, Byung Ihn Choi, Ronnie T. P. Poon, Shuichiro Shiina, Ann Lii Cheng, Ji-Dong Jia, Shuntaro Obi, Kwang Hyub Han, Wasim Jafri, Pierce Chow, Seng Gee Lim, Yogesh K. Chawla, Unggul Budihusodo, Rino A. Gani, C. Rinaldi Lesmana, Terawan Agus Putranto, Yun Fan Liaw, Shiv Kumar Sarin, Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma, Hepatology International, 2010, 4, 2, 439

    CrossRef

  26. 26
    Massimo Colombo, Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons, Digestive and Liver Disease, 2010, 42, S298

    CrossRef

  27. 27
    Yun-Fan Liaw, Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros, Digestive and Liver Disease, 2010, 42, S293

    CrossRef

  28. 28
    James Fung, Ching-Lung Lai, Man-Fung Yuen, Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B, Expert Review of Anti-infective Therapy, 2010, 8, 6, 717

    CrossRef

  29. 29
    Jessica Liu, Hwai–I. Yang, Mei–Hsuan Lee, Sheng–Nan Lu, Chin–Lan Jen, Li–Yu Wang, San–Lin You, Uchenna H. Iloeje, Chien–Jen Chen, Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study, Gastroenterology, 2010, 139, 2, 474

    CrossRef

  30. 30
    George V. Papatheodoridis, Pietro Lampertico, Spilios Manolakopoulos, Anna Lok, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review, Journal of Hepatology, 2010, 53, 2, 348

    CrossRef

  31. 31
    Hyun Woong Lee, Heon Ju Lee, Jae Seok Hwang, Joo Hyun Sohn, Jae Young Jang, Ki Jun Han, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong Han Paik, Chun Kyon Lee, Kwan Sik Lee, Chae Yoon Chon, Kwang-Hyub Han, Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B, Hepatology, 2010, 51, 2
  32. 32
    Yong-Feng Yang, Wei Zhao, Hai-Ming Xia, Yan-Dan Zhong, Ping Huang, Jian Wen, Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: A meta-analysis, Antiviral Research, 2010, 85, 2, 361

    CrossRef

  33. 33
    G. L.-H. Wong, K. K.-L. Yiu, V. W.-S. Wong, K. K.-F. Tsoi, H. L.-Y. Chan, Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2010, 32, 9
  34. 34
    R. Moucari, P. Marcellin, Négativation de l’antigène HBs : valeur pronostique pour la réponse au traitement et l’évolution à long terme, Gastroentérologie Clinique et Biologique, 2010, 34, S119

    CrossRef

  35. 35
    R. B. Takkenberg, C. J. Weegink, H. L. Zaaijer, H. W. Reesink, New developments in antiviral therapy for chronic hepatitis B, Vox Sanguinis, 2010, 98, 4
  36. 36
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  37. 37
    Alajos Pár, A vírushepatitisek megelőzése és antivirális kezelése mint a hepatocellularis carcinoma (HCC) prevenciója, Orvosi Hetilap, 2009, 150, 1, 19

    CrossRef

  38. 38
    Byung Kook Kim, So Young Kwon, Chang Hong Lee, Won Hyeok Choe, Hong Mi Choi, Hye Won Koo, Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea, The Korean Journal of Hepatology, 2009, 15, 1, 25

    CrossRef

  39. 39
    Yu-mei Wen, Antigen–antibody immunogenic complex: promising novel vaccines for microbial persistent infections, Expert Opinion on Biological Therapy, 2009, 9, 3, 285

    CrossRef

  40. 40
    Robert Perrillo, Benefits and risks of interferon therapy for hepatitis B, Hepatology, 2009, 49, S5
  41. 41
    Jung-mi Kim, Byung-Ho Choe, Mi Ae Chu, Seung Man Cho, Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B, The Korean Journal of Hepatology, 2009, 15, 2, 168

    CrossRef

  42. 42
    James Fung, Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic, Expert Review of Anti-infective Therapy, 2009, 7, 8, 945

    CrossRef

  43. 43
    T. Poynard, J. Massard, M. Rudler, A. Varaud, P. Lebray, J. Moussalli, M. Munteanu, Y. Ngo, D. Thabut, Y. Benhamou, V. Ratziu, Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials, Gastroentérologie Clinique et Biologique, 2009, 33, 10-11, 916

    CrossRef

  44. 44
    Y.-F. Yang, W. Zhao, Y.-D. Zhong, H.-M. Xia, L. Shen, N. Zhang, Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis, Journal of Viral Hepatitis, 2009, 16, 4
  45. 45
    James Fung, Ching-Lung Lai, Yasuhito Tanaka, Masashi Mizokami, John Yuen, Danny Ka-Ho Wong, Man-Fung Yuen, The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion, The American Journal of Gastroenterology, 2009, 104, 8, 1940

    CrossRef

  46. 46
    Steven K. Herrine, Simona Rossi, Victor J. Navarro, Pharmacology and Therapeutics, 2009,

    CrossRef

  47. 47
    Ching-Lung Lai, Man-Fung Yuen, Chronic Hepatitis B — New Goals, New Treatment, New England Journal of Medicine, 2008, 359, 23, 2488

    CrossRef

  48. 48
    Pin-Nan Cheng, Ting-Tsung Chang, Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients, Expert Review of Anti-infective Therapy, 2008, 6, 5, 569

    CrossRef

  49. 49
    James Fung, Ching-Lung Lai, Man-Fung Yuen, LB80380: a promising new drug for the treatment of chronic hepatitis B, Expert Opinion on Investigational Drugs, 2008, 17, 10, 1581

    CrossRef

  50. 50
    J. J. Y. SUNG, K. K. F. TSOI, V. W. S. WONG, K. C. T. LI, H. L. Y. CHAN, Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma, Alimentary Pharmacology & Therapeutics, 2008, 28, 9
  51. 51
    James Fung, Ching-Lung Lai, Man-Fung Yuen, New paradigms for the treatment of chronic hepatitis B, Journal of Gastroenterology and Hepatology, 2008, 23, 8pt1
  52. 52
    Nancy Leung, Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues, Hepatology International, 2008, 2, 2, 163

    CrossRef

  53. 53
    Teerha Piratvisuth, Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B, Hepatology International, 2008, 2, 2, 140

    CrossRef

  54. 54
    K. Luo, Q. Mao, P. Karayiannis, D. Liu, Z. Liu, Y. Zhou, X. Feng, Y. Zhu, Y. Guo, R. Jiang, F. Zhou, J. Peng, J. Hou, Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study, Journal of Viral Hepatitis, 2008, 15, 9
  55. 55
    Jinlin Hou, You-Kuan Yin, Daozhen Xu, Deming Tan, Junqi Niu, Xiaqiu Zhou, Yuming Wang, Limin Zhu, Yongwen He, Hong Ren, Mobin Wan, Chengwei Chen, Shanming Wu, Yagang Chen, Jiazhang Xu, Qinhuan Wang, Lai Wei, George Chao, Barbara Fielman Constance, George Harb, Nathaniel A. Brown, Jidong Jia, Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial, Hepatology, 2008, 47, 2
  56. 56
    George V Papatheodoridis, Spilios Manolakopoulos, Geoffrey Dusheiko, Athanasios J Archimandritis, Therapeutic strategies in the management of patients with chronic hepatitis B virus infection, The Lancet Infectious Diseases, 2008, 8, 3, 167

    CrossRef

  57. 57
    G. Carosi, M. Rizzetto, Treatment of chronic hepatitis B: Recommendations from an Italian workshop, Digestive and Liver Disease, 2008, 40, 8, 603

    CrossRef

  58. 58
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  59. 59
    Man-Fung Yuen, Ching-Lung Lai, Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential?, The American Journal of Gastroenterology, 2007, 102, 1, 105

    CrossRef

  60. 60
    Shoji Kubo, Hiromu Tanaka, Shigekazu Takemura, Satoshi Yamamoto, Seikan Hai, Tsuyoshi Ichikawa, Shintaro Kodai, Hiroji Shinkawa, Hiroki Sakaguchi, Akihiro Tamori, Daiki Habu, Shuhei Nishiguchi, Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus, Hepatology Research, 2007, 37, 2
  61. 61
    Takashi Someya, Kenji Ikeda, Satoshi Saitoh, Masahiro Kobayashi, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada, Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis, Journal of Gastroenterology, 2007, 41, 12, 1206

    CrossRef

  62. 62
    Shi-Ming Lin, Ming-Lung Yu, Chuan-Mo Lee, Rong-Nan Chien, I-Shyan Sheen, Chia-Ming Chu, Yun-Fan Liaw, Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma, Journal of Hepatology, 2007, 46, 1, 45

    CrossRef

  63. 63
    Hong Koh, Seoung Yon Baek, Ki Sup Chung, Lamivudine Therapy for Korean Children with Chronic Hepatitis B, Yonsei Medical Journal, 2007, 48, 6, 927

    CrossRef

  64. 64
    Byung-Ho Choe, Ji Hye Lee, You Cheol Jang, Chang Hwan Jang, Ki Won Oh, Soonhak Kwon, Myung Chul Hyun, Cheol Woo Ko, Kun Soo Lee, Won Kee Lee, Long-term Therapeutic Efficacy of Lamivudine Compared With Interferon-α in Children with Chronic Hepatitis B: The Younger the Better, Journal of Pediatric Gastroenterology and Nutrition, 2007, 44, 1, 92

    CrossRef

  65. 65
    Anna Suk–Fong Lok, Navigating the Maze of Hepatitis B Treatments, Gastroenterology, 2007, 132, 4, 1586

    CrossRef

  66. 66
    K. Luo, H. He, Z. Liu, Y. Zhu, Q. Mao, W. Liang, No significant differences in histology and response to interferon treatment in hepatitis B carriers of genotypes C and recombinant B, Journal of Viral Hepatitis, 2007, 14, 6
  67. 67
    Morris Sherman, Screening for hepatocellular carcinoma, Hepatology Research, 2007, 37,
  68. 68
    Byung-Ho Choe, The management and treatment of chronic hepatitis B in Korean children, Korean Journal of Pediatrics, 2007, 50, 9, 823

    CrossRef

  69. 69
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 2, 425

    CrossRef

  70. 70
    F. Blaine Hollinger, Daryl T.-Y. Lau, Hepatitis B: The Pathway to Recovery Through Treatment, Gastroenterology Clinics of North America, 2006, 35, 4, 895

    CrossRef

  71. 71
    Hitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, Norio Akuta, Takashi Someya, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada, Long-Term Follow-Up of HBeAg-Positive Young Adult Japanese Patients Treated with Corticosteroid Withdrawal Therapy for Chronic Hepatitis B, Intervirology, 2006, 49, 6, 339

    CrossRef

  72. 72
    Steven-Huy B Han, Natural Course, Therapeutic Options and Economic Evaluation of Therapies for Chronic Hepatitis B, Drugs, 2006, 66, 14, 1831

    CrossRef

  73. 73
    Hyung Joon Yim, Anna Suk-Fong Lok, Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005, Hepatology, 2006, 43, S1
  74. 74
    Morris Sherman, Optimizing Management Strategies in Special Patient Populations, The American Journal of Gastroenterology, 2006, 101, S1, S26

    CrossRef

  75. 75
    James Fung, Ching-Lung Lai, Man-Fung Yuen, Overcoming the problem of chronic hepatitis B, Drug Discovery Today: Therapeutic Strategies, 2006, 3, 2, 197

    CrossRef

  76. 76
    M. SHERMAN, Personal view: the management of chronic hepatitis B infection, Alimentary Pharmacology & Therapeutics, 2006, 23, 7
  77. 77
    Hui-Chuan Sun, Zhao-You Tang, Lu Wang, Lun-Xiu Qin, Zeng-Chen Ma, Qin-Hai Ye, Bo-Heng Zhang, Yong-Bin Qian, Zhi-Quan Wu, Jia Fan, Xin-Da Zhou, Jian Zhou, Shuang-Jian Qiu, Yue-Fang Shen, Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial, Journal of Cancer Research and Clinical Oncology, 2006, 132, 7, 458

    CrossRef

  78. 78
    Man-Fung Yuen, Ching-Lung Lai, Recommendations and potential future options in the treatment of hepatitis B, Expert Opinion on Pharmacotherapy, 2006, 7, 16, 2225

    CrossRef

  79. 79
    Ira M. Jacobson, Therapeutic Options for Chronic Hepatitis B: Considerations and Controversies, The American Journal of Gastroenterology, 2006, 101, S1, S13

    CrossRef

  80. 80
    T. Berg, Therapie der Hepatitis B, Der Gastroenterologe, 2006, 1, 2, 117

    CrossRef

  81. 81
    Jia-Horng Kao, Ding-Shinn Chen, Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia, Liver International, 2005, 25, 4
  82. 82
    Katherine A. McGlynn, W.Thomas London, Epidemiology and natural history of hepatocellular carcinoma, Best Practice & Research Clinical Gastroenterology, 2005, 19, 1, 3

    CrossRef

  83. 83
    Flor H Pujol, Marisol Devesa, Genotypic Variability of Hepatitis Viruses Associated With Chronic Infection and the Development of Hepatocellular Carcinoma, Journal of Clinical Gastroenterology, 2005, 39, 7, 611

    CrossRef

  84. 84
    Jordi Bruix, Morris Sherman, Management of hepatocellular carcinoma, Hepatology, 2005, 42, 5
  85. 85
    Scott K. Fung, Anna S.F. Lok, Management of patients with hepatitis B virus-induced cirrhosis, Journal of Hepatology, 2005, 42, 1, S54

    CrossRef

  86. 86
    G.H. Zacharakis, J. Koskinas, S. Kotsiou, M. Papoutselis, F. Tzara, N. Vafeiadis, A.J. Archimandritis, K. Papoutselis, Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project), Journal of Medical Virology, 2005, 77, 2
  87. 87
    Michael C. KEW, Prevention of hepatocellular carcinoma, HPB, 2005, 7, 1
  88. 88
    Antonio Craxì, Calogero Cammà, Prevention of Hepatocellular Carcinoma, Clinics in Liver Disease, 2005, 9, 2, 329

    CrossRef

  89. 89
    Morris Sherman, Screening for hepatocellular carcinoma, Best Practice & Research Clinical Gastroenterology, 2005, 19, 1, 101

    CrossRef

  90. 90
    Man-Fung Yuen, Ching-Lung Lai, Telbivudine: an upcoming agent for chronic hepatitis B, Expert Review of Anti-infective Therapy, 2005, 3, 4, 489

    CrossRef

  91. 91
    Emmet B. Keeffe, Douglas T. Dieterich, Steve-huy B. Han, Ira M. Jacobson, Paul Martin, Eugene R. Schiff, Hillel Tobias, Teresa L. Wright, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States, Clinical Gastroenterology and Hepatology, 2004, 2, 2, 87

    CrossRef

  92. 92
    Daryl T.-Y. Lau, Fernando E. Membreno, Antiviral therapy for treatment-naı̈ve hepatitis B virus patients, Gastroenterology Clinics of North America, 2004, 33, 3, 581

    CrossRef

  93. 93
    S.-M. Lin, D.-I. Tai, R.-N. Chien, I.-S. Sheen, C.-M. Chu, Y.-F. Liaw, Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B, Journal of Viral Hepatitis, 2004, 11, 4
  94. 94
    Man-Fung Yuen, Danny Ka-Ho Wong, Erwin Sablon, Eric Tse, Irene Oi-Lin Ng, He-Jun Yuan, Chung-Wah Siu, Tamara J. Sander, Eric J. Bourne, Jeff G. Hall, Lynn D. Condreay, Ching-Lung Lai, HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects, Hepatology, 2004, 39, 6
  95. 95
    SK SARIN, MANOJ KUMAR, PANKAJ TYAGI, HBV carrier or chronic HBV infection: Need for change in terminology, Journal of Gastroenterology and Hepatology, 2004, 19,
  96. 96
    Wei Xiong, Xun Wang, Xiaoying Liu, Li Xiang, Lingjie Zheng, Zhenghong Yuan, Interferon-inducible MyD88 protein inhibits hepatitis B virus replication, Virology, 2004, 319, 2, 306

    CrossRef

  97. 97
    Yun-Fan Liaw, Joseph J.Y. Sung, Wan Cheng Chow, Geoffrey Farrell, Cha-Ze Lee, Hon Yuen, Tawesak Tanwandee, Qi-Min Tao, Kelly Shue, Oliver N. Keene, Jonathan S. Dixon, D. Fraser Gray, Jan Sabbat, Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease, New England Journal of Medicine, 2004, 351, 15, 1521

    CrossRef

  98. 98
    Monika van Zonneveld, Pieter Honkoop, Bettina E. Hansen, Hubertus G.M. Niesters, Sarwa Darwish Murad, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B, Hepatology, 2004, 39, 3
  99. 99
    Morris Sherman, Pathogenesis and screening for hepatocellular carcinoma, Clinics in Liver Disease, 2004, 8, 2, 419

    CrossRef

  100. 100
    Xenia Hom, Nancy R. Little, Stephen D. Gardner, Maureen M. Jonas, Predictors of Virologic Response to Lamivudine Treatment in Children With Chronic Hepatitis B Infection, The Pediatric Infectious Disease Journal, 2004, 23, 5, 441

    CrossRef

  101. 101
    YUN-FAN LIAW, Role of antiviral therapy of HBV in the prevention of cirrhosis and hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2004, 19,
  102. 102
    Morris Sherman, Yuji Takayama, Screening and treatment for hepatocellular carcinoma, Gastroenterology Clinics of North America, 2004, 33, 3, 671

    CrossRef

  103. 103
    Man-Fung Yuen, Ching-Lung Lai, Treatment for Hepatitis B, Journal of Clinical Gastroenterology, 2004, 38, S134

    CrossRef

  104. 104
    W.Graham Cooksley, Treatment of hepatitis B with interferon and combination therapy, Clinics in Liver Disease, 2004, 8, 2, 353

    CrossRef

  105. 105
    Byung-Cheol Song, Dong Jin Suh, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Which Patients With Chronic Hepatitis B Are More Likely to Relapse After Interferon Alpha-Induced Hepatitis B e Antigen Loss in Korea?, Journal of Clinical Gastroenterology, 2004, 38, 2, 124

    CrossRef

  106. 106
    Paloma Jara, Loreto Hierro, Hepatitis B y C en niños, Anales de Pediatría Continuada, 2003, 1, 2, 71

    CrossRef

  107. 107
    Antonio Craxı̀, Danilo Di Bona, Calogero Cammà, Interferon-α for HBeAg-positive chronic hepatitis B, Journal of Hepatology, 2003, 39, 99

    CrossRef

  108. 108
    Giovanna Fattovich, Natural history of hepatitis B, Journal of Hepatology, 2003, 39, 50

    CrossRef

  109. 109
    David E Kaplan, K.Rajender Reddy, Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes, Clinics in Liver Disease, 2003, 7, 3, 683

    CrossRef

  110. 110
    Necati Örmeci, Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN, Fundamental & Clinical Pharmacology, 2003, 17, 6
  111. 111
    José M. Sánchez-Tapias, Josep Costa, Antoni Mas, Miquel Bruguera, Juan Rodés, Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients, Gastroenterology, 2002, 123, 6, 1848

    CrossRef

  112. 112
    Kathryn Z. Guyton, Thomas W. Kensler, Prevention of liver cancer, Current Oncology Reports, 2002, 4, 6, 464

    CrossRef

  113. 113
    Ricardo Marrero, Eugene Schiff, Viral hepatitis, Current Opinion in Gastroenterology, 2002, 18, 3, 330

    CrossRef

  114. 114
    Man-Fung Yuen, Ching-Lung Lai, Treatment of chronic hepatitis B, The Lancet Infectious Diseases, 2001, 1, 4, 232

    CrossRef

  115. 115
    Hugh J. Field, Richard J. Whitley, Antiviral Chemotherapy, Topley and Wilson's Microbiology and Microbial Infections,
  116. 116
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,
  117. 117
    Piero Luigi Almasio, Calogero Cammà, Vito Di Marco, Antonio Craxì, Hepatitis B: Prognosis and Treatment,